Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Grant
Filed:
February 27, 2017
Date of Patent:
May 28, 2019
Assignee:
Wyeth Holdings LLC
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
Type:
Grant
Filed:
March 5, 2018
Date of Patent:
May 21, 2019
Assignee:
Wyeth LLC
Inventors:
Eric J. Benjamin, Wendy A. Dulin, Yanning Lin, Kai Zhuang
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Type:
Application
Filed:
December 13, 2018
Publication date:
April 25, 2019
Applicant:
Wyeth, LLC
Inventors:
Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Type:
Application
Filed:
December 13, 2018
Publication date:
April 25, 2019
Applicant:
Wyeth, LLC
Inventors:
Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
Abstract: An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
March 26, 2019
Assignee:
Wyeth LLC
Inventors:
Jay Dickerson, William Mark, Annabelle Trimmer, David Jaeger, Amanda Alley
Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
February 5, 2019
Assignee:
Wyeth LLC
Inventors:
Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
Type:
Application
Filed:
July 30, 2018
Publication date:
November 29, 2018
Applicant:
Wyeth Holdings LLC
Inventors:
Arthur KUNZ, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and method for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
Abstract: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
Type:
Grant
Filed:
March 20, 2017
Date of Patent:
July 31, 2018
Assignee:
WYETH LLC
Inventors:
Qinghong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi
Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
Type:
Application
Filed:
January 30, 2018
Publication date:
June 14, 2018
Applicant:
WYETH LLC
Inventors:
Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Sreekumar R. KODANGATTIL
Abstract: The present disclosure provides a method of reducing protein misfolding and aggregation in the cell culture by growing the cell culture at a reduced temperature and/or reduced pH. As a result, the quality of the protein produced in the cell culture is greatly improved. Thus, the present disclosure facilitates improvements in the efficacy of therapeutic proteins produced in cell culture.
Type:
Grant
Filed:
April 22, 2008
Date of Patent:
June 5, 2018
Assignee:
Wyeth LLC
Inventors:
Jose Manuel Gomes, Gregory Walter Hiller
Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
Type:
Grant
Filed:
February 12, 2016
Date of Patent:
May 29, 2018
Assignee:
Wyeth LLC
Inventors:
William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.
Abstract: The present invention comprises a cap (101) having a chamber and a packaging unit having this cap (101) attached to a container. A membrane (405) separates the chamber in the cap from a reservoir in the container, so that two different components may be kept separate until ready to use. The cap (101) has a collapsible (102) button with a piercing element so that when the button (102) is pressed the membrane (405) is pierced and the contents of the chamber and reservoir may be mixed together.
Type:
Grant
Filed:
March 22, 2012
Date of Patent:
May 22, 2018
Assignee:
Wyeth LLC
Inventors:
Jeffrey Martin Davis, Helen Marie Moore
Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
Type:
Grant
Filed:
January 22, 2015
Date of Patent:
March 27, 2018
Assignee:
Wyeth LLC
Inventors:
Frank S. Walsh, Margaret M. Zaleska, David S. Howland, Lioudmila Tchistiakova, Riyez Karim, Pamela Kelley, Xiang-Yang Tan, Seung Poon Kwak, Menelas N. Pangalos
Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
Type:
Grant
Filed:
December 16, 2015
Date of Patent:
February 27, 2018
Assignee:
WYETH LLC
Inventors:
Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Sreekumar R. Kodangattil
Abstract: The present invention provides methods of lyophilizing a pharmaceutical substance involving a primary drying step executed at a product temperature at or above the collapse temperature. The invention also provides pharmaceutical substances lyophilized at or above the collapse temperature.
Type:
Grant
Filed:
August 5, 2009
Date of Patent:
February 6, 2018
Assignee:
Wyeth LLC
Inventors:
Serguei Tchessalov, Dan Dixon, Nicholas Warne
Abstract: The present invention provides a new forms of (R)-N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
Type:
Grant
Filed:
April 6, 2015
Date of Patent:
January 2, 2018
Assignee:
WYETH LLC
Inventors:
John Wozney, Howard Seeherman, Christopher Todd Brown